Science

The unique TetraKit Platform redefines radiopharmaceutical manufacture by using pre-formed radiolabeled tetrazines. A single batch of these tetrazines can produce a library of radiopharmaceuticals at a centralized facility, or alternatively be shipped to clinical centers for on-site preparation of the final compound via simple click chemistry, with minimal training necessary. This reduces the need for dedicated equipment and consumables, as well is lengthy and expensive optimization of radiosynthesis for each specific radiopharmaceutical. With the TetraKit Platform, this is concentrated in a single compound, the tetrazine one-fits-all building block. The kit-based approach ensures easy implementation in radiopharmacies. TetraKit Technologies is developing the commercial consumables needed, such as GMP-grade precursors, cassettes and cold kits, and automated methods for commercial modules, to enable tech transfer and establishment at any radiopharmacy.

Theranostics is a powerful emerging concept within nuclear medicine, and especially oncology. It combines radioligand therapy with imaging-based diagnostics, relying on complementary pairs of radiopharmaceutical. In theranostics, the same targeting vector is labeled with radionuclides, that are either therapeutic or diagnostic, and sometimes both. Theranostics is therefore ideal for diagnosing, treating and monitoring metastatic cancer, offering solutions where chemotherapy fails and even potential as first-line treatment. The TetraKit Platform enables the seamless switching between alpha- and beta-emitting therapeutic radionuclides with PET and SPECT diagnostics on the same molecule, enabling the full spectrum of theranostic applications.